Prospective Randomized Trial of Hepatic Artery Chemotherapy With Cisplatin and Doxorubicin, With or Without Lipiodol in the Treatment of Advanced Stage Hepatocellular Carcinoma

Journal of Clinical Gastroenterology

Volumn 45, Issue 9, 2011, Pages e87-e91

  Carr, Brian Irving ^a   Bron, Klaus ^a   Swanson, Dennis P ^b  

^a Departments of Liver Transplantation   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Chemoembolization; Cisplatin; Doxorubicin; HCC; Lipiodol

Indexed keywords

CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CHEMOTHERAPY; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; EMULSION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ARTERY CHEMOTHERAPY; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; VASCULARIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DISEASE PROGRESSION; DOXORUBICIN; ETHIODIZED OIL; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052925637     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31820fb274     Document Type: Article

References (25)

1. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review Eur J Cancer. 2004;40:1474-1484
2. Carr BI, Pancoska P, Branch RA. HCC in young adults Hepatogastroenterology. 2010;57:436-440
3. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst. 2005;97:1532-1538
4. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials Alimentary Pharmacol Ther. 2006;23:1535-1547
5. Lencioni R. Loco-Regional treatment of hepatocellular carcinoma Hepatology. 2010 Epub
6. Pleguezuelo M, Marelli L, Misseri M, et al. TACE versus TAE as therapy for hepatocellular carcinoma Expert Rev Anticancer Ther. 2008;8:1623-1641
7. Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma Korean J Radiol. 2009;10:425-434
8. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? a systematic review of cohort and randomized studies Cardiovasc Intervent Radiol. 2007;30:6-25
9. Lo C, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology. 2002;35:1164-1171
10. Llovet J, Real M, Montana X, et al. Arterial embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial Lancet. 2002;359:1734-1739
11. Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anti-cancer treatment with an oily anti-cancer drug injected into the ligated feeding hepatic artery for liver cancer Cancer. 1983;52:2193-2200
12. Okayasu I, Hatakeyama S, Yoshida T, et al. Selective and persistent deposition and gradual drainage of iodized oil, Lipiodol in the hepatocellular carcinoma after injection into the feeding hepatic artery Am J Clin Pathol. 1988;90:536-544
13. Yu S, Leung W, Lau W, et al. A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans Cardiovasc Intervent Radiol. 2008;31:289-298
14. Satake M, Uchida H, Arai Y, et al. Transcatheter arterial chemoembolization (TACE) with Lipiodol to treat hepatocellular carcinoma: Survey results from the TACE study group of Japan Cardiovasc Intervent Radiol. 2008;31:756-761
15. Bhattacharya S, Novell J, Winslet M, et al. Iodized oil in the treatment of hepatocellular carcinoma Br J Surg. 1994;81:1563-1571
16. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin and gelatin sponge Cancer. 1987;60:1194-1203
17. Maeda S, Fjuiyama S, Tanaka M, et al. Survival and local recurrence rates of hepatocellular carcinoma patients treated by transarterial chemolipiodolization with and without embolization Hepatol Res. 2002;23:202-210
18. Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents Radiology. 1987;163:345-351
19. Fujita T, Ito K, Tanabe M, et al. Iodized oil accumulation in hypervascular hepatocellular carcinoma after transcatheter arterial chemoembolizaton: comparison of imaging findings with CT during hepatic arteriography J Vasc Interv Radiol. 2008;19:333-341
20. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma Cancer Chemother Pharmacol. 1994;33:S149-152
21. Couto OFM, Dvorchik I, Carr BI. Causes of death in patients with hepatocellular carcinoma Dig Dis Science. 2007;52:3285-3289
22. Kuroda C, Sakurai M, Monden M, et al. Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma: a study in resected cases Cancer. 1991;67:81-86
23. Carr BIEds-Livraghi T, Makuuchi M, Buscarini L. Chemotherapy for HCC Diagnosis and treatment of hepatocellular carcinoma. 1997 Cambridge, UK Greenwich Medical Media (Cambridge University Press):369-391
24. Utsonomiya T, Shimada M, Imura S, et al. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma J Gastroenterol. 2010;45:146-152
25. Carr BI, Pancoska P, Branch RA. HCC in young adults Hepatogastroenterology. 2010;57:436-440